NCT00335192 - To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

HIV

Interventions

DRUG

Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks

3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)

DRUG

Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks

ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)

DRUG

Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks

3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).

Trial Locations (1)

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors

collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Germans Trias i Pujol Hospital

OTHER